Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
ListedSMEHospital & Healthcare ServicesINVICTA

Invicta Diagnostic IPO

Invicta Diagnostic IPO is an SME IPO raising ₹28 Cr at ₹80 – ₹85 a share. It listed on 8 Dec 2025 at ₹100, +17.6% against its issue price of ₹85, and trades at ₹68 today (−20.0% since issue). It was subscribed 4.02× in total.

Get alerts on this companyCompany pageProspectus ↗
₹85
Issue price
₹68
Price now
−20.0%
Since issue price
8 Dec 2025
Listed on
4.02×Subscribed (final) · all exchanges

4.0 times more demand than shares on offer

populated partly populated we hold nothing here — the tab says why

How its cohort has done

268 SME issues listed in 2025 that we can price today. This is the group this issue belongs to.

−7.6%
Median return since issue price
54.1%
Now trading below their issue price

Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →

What we hold for this issue

Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.

Category split — who bidNot available from NSE for this issue
How demand built over timeFinal figure held, but no series — we were not sampling this issue while it was live
Price-point demand curveLive only — NSE stops serving this once bidding closes
Lead managers and registrar1 bank
Official documents4 documents
Listing-day priceOpened at ₹100 on debut
Performance since listingComputed from our own daily closes

Led by Socradamus Capital Private Limited — median −20.0% across the 5 of its issues we can price. All lead managers →

What happens when

28 NovPre-apply
1 DecBidding opens
3 DecBidding closes
5 DecAllotment
5 DecRefunds
8 DecListing
14 JanMandate ends

Track INVICTA DIAGNOSTIC LTD

Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.

Open the company page

Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.